Key Points {#d30e179}
==========

Following a recent non--peer-reviewed publication describing fatal toxicity of hydroxychloroquine in association with metformin in mice, the present study was undertaken to investigate this putative drug--drug interaction between hydroxychloroquine and metformin using pharmacovigilance data.Using VigiBase^®^, the WHO pharmacovigilance database, we found an increased risk of fatal outcomes with the association in comparison with each of the two drugs when used alone.This study suggests a pharmacovigilance signal of fatal outcome with the association hydroxychloroquine + metformin that should be confirmed by further studies.

Introduction {#Sec1}
============

Hydroxychloroquine is an antimalarial drug, today widely used in rheumatoid arthritis or systemic lupus erythematous \[[@CR1]\], that was recently proposed to treat COVID-19 infections \[[@CR2], [@CR3]\], despite lack of clinical evidence \[[@CR4]\]. Besides efficacy, its clinical pharmacology (safety, drug--drug interactions) particularly in COVID-19 patients is not well known. In fact, a recent non--peer-reviewed publication (available in a preprint server) from American oncologists described fatal toxicity of hydroxychloroquine (or of chloroquine) in association with metformin in mice \[[@CR5]\].

Objective {#Sec2}
=========

These aforementioned results led us to investigate the reality of this putative drug--drug interaction in humans using a pharmacovigilance database. In fact, previous studies have shown that pharmacovigilance databases can be successfully used to detect drug--drug interactions \[[@CR6]\].

Methods {#Sec3}
=======

The study was performed in VigiBase^®^, the WHO pharmacovigilance database, which registers all Individual Case Safety Reports (ICSRs) from more than 130 countries around the world. ICSRs are entered into VigiBase^®^ after rigorous quality checks and deduplication \[[@CR7]\].

We extracted all ICSRs registered between 1 January 2000 and 31 December 2019 as 'fatal outcomes' \[High Level Group Term (HLGT) in the System Organ Class (SOC) group 'General Disorders and Administration Site Conditions' according to the Medical Dictionary for Regulatory Activities (MedDRA^®^)\] in patients aged between 18 and 64 years. We excluded ICSRs from patients with sex unknown as well as those \< 18 years and \> 64 years because in a preliminary analysis of VigiBase^®^ we failed to find any fatal outcome with the drug association (hydroxychloroquine + metformin) in patients aged \< 18 and \> 64 years. Following current protocols to detect a pharmacovigilance signal in large pharmacovigilance databases \[[@CR8]\], we performed a disproportionality analysis (case/non-case analysis) \[[@CR8]\], with cases being occurrence of 'fatal outcomes' with hydroxychloroquine (or chloroquine) (P01BA according to ATC classification of drugs) and non-cases all other ICSRs with hydroxychloroquine (or chloroquine) alone. Data with hydroxychloroquine (or chloroquine) alone were compared with the association hydroxychloroquine (or chloroquine) + metformin (A10BA). We also performed such analyses including other drugs used in diabetes mellitus; that is, sulfonylureas (A10BB), alpha glucosidase inhibitors (A10BF), thiazolidinediones (A10BG), dipeptidyl peptidase 4 (DPP-4) inhibitors (A10BH), glucagon like peptide-1 (GLP-1) analogues (A10BJ) and sodium glucose cotransporter 2 (SGLT2) inhibitors (A10BK).

Results are presented as reporting odds ratio (ROR), a concept similar to OR in case control studies, with its 95% confidence interval (CI).

Results {#Sec4}
=======

Of the 21,580,375 deduplicated ICSRs recorded in VigiBase^®^, 7,961,942 met the inclusion criteria defined above with 10,771 involving hydroxychloroquine and 52 recorded as 'fatal outcomes' with this drug. These 52 ICSRs were registered mainly in women (78.8%), with the main age group 45--64 years (55.8%). The majority came from the United States of America (US) (80.8%). Among these 52 ICSRs, 30 were described as 'completed suicides'. With metformin, 1413 deaths were found (including 1083 suicides), 58.6% in men, mainly coming from the US (94.1%). The most frequent age group was 45--64 years (65.6%). Seven deaths were registered with the association hydroxychloroquine + metformin with three reports in individuals aged 18--44 years and four aged 45--64 years. Four were observed in men and six were registered as completed suicides. All were from the US (Table [1](#Tab1){ref-type="table"}).Table 1Number of total, fatal, non-suicidal reports and their ratios registered with hydroxychloroquine, metformin and their association in VigiBase^®^, the WHO pharmacovigilance database, between 1 January 2000 and 31 December 2019Total reportsFatal reportsNon-suicidal fatal reportsSuicidal fatal/non-suicidal fatal ratio ((%)Non-suicidal fatal/total reports ratio (%)Hydroxychloroquine10,77152221360.20Metformin31,58214133303280.10Hydroxychloroquine + metformin32716003.12

For the total fatal reports, an ROR value of 57.7 (23.9--139.3) was associated with hydroxychloroquine + metformin in comparison with hydroxychloroquine alone. In comparison with metformin alone, the association hydroxychloroquine + metformin was associated with ROR 6.0 (2.6--13.8). After excluding suicides, similar results were obtained for the association hydroxychloroquine + metformin versus hydroxychloroquine alone: ROR 15.8 (2.1--120.6).

No ICSR combining hydroxychloroquine and other drugs used in diabetes (sulfonylureas, alpha glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogues, SGLT2 inhibitors) was found in VigiBase^®^.

For chloroquine, 15 deaths were registered (60.0% in women, 73.3% aged 18--44 years, including eight completed suicides. No fatal outcome was registered for the association chloroquine + metformin (or other drugs used in diabetes).

Discussion {#Sec5}
==========

The present study was performed to search for a possible drug--drug interaction between hydroxychloroquine + metformin related to the recently developed off-label use of hydroxychloroquine in the field of COVID-19. In addition, some studies have investigated hydroxychloroquine in association with metformin in diabetic patients to achieve a better control of type-2 diabetes conditions \[[@CR10]\]. Conversely, metformin was studied as an adjunctive therapy for systemic lupus erythematous, a condition for which hydroxychloroquine is routinely administered \[[@CR11]\]. In fact, our study was prompted by the paper from Rajeshkumar's group \[[@CR5]\] showing a higher mortality ratio (30--40%) in mice treated with hydroxychloroquine + metformin in comparison with the control group receiving metformin alone. The authors found an increased number of autophagosomes in the heart, liver and kidneys of mice treated with the combination. They did not conclude about a univocal mechanism for their observation but suggested a synergistic effect between metformin, an inhibitor of the mitochondrial complex I, and hydroxychloroquine, which inhibits autophagy \[[@CR5]\].

Our study did not allow for discussion of the possible mechanism of action but shows a safety signal with the association hydroxychloroquine + metformin. We found that more reports of fatal outcomes (and especially suicides) are registered in VigiBase^®^ with the association than with each of the drugs administered individually. No conclusion can be made for chloroquine due to the absence of lethal reports with the association.

Of course, our work suffers from the classical biases of all pharmacovigilance studies: under- or selective reporting and lack of systematic information on doses and duration of exposure in VigiBase^®^. Of course, it is important to underline that ROR investigates the risk of ADR reporting rather than a true risk. Our study was not performed in COVID-19 patients but in those receiving hydroxychloroquine for rheumatic or dermatologic diseases. However, there is no reason to believe that the described drug--drug interaction could depend on the underlying disease(s). It was not possible to perform direct adjustments due to the characteristics of VigiBase^®^. However, Seabroke's group found that in large pharmacovigilance databases, subgroup analyses (as performed in this study) improve both sensitivity and precision and are clearly beneficial over crude analyses \[[@CR12], [@CR13]\].

The fact that the completed suicide/non-suicidal ratio is higher for the association than with the drugs alone could suggest an additional toxicity of hydroxychloroquine and metformin taken together. Since hydroxychloroquine doses are higher for COVID-19 than for lupus or rheumatoid arthritis, this might increase the significance of the signal.

In contrast, the results of the present study have several important strengths. They are reflective of clinical conditions and cases were retrieved from the world's largest pharmacovigilance database. It used a validated method for the first detection of pharmacovigilance signals \[[@CR7]--[@CR9]\]. We found high significant values of ROR suggesting a true association between the investigated factors. Our results extend the conclusions obtained in animals by Rajeshkumar et al. \[[@CR5]\] and should be considered as a meaningful pharmacovigilance signal of a drug--drug interaction between hydroxychloroquine and metformin. In fact, metformin is a widely used drug, particularly in aged and/or obese patients that are found to be particularly at risk for COVID-19 pandemic infection \[[@CR14]\].

Conclusion {#Sec6}
==========

The present study found a pharmacovigilance signal that should be confirmed by other studies using other methods for drug--drug interaction detection. Our data suggest that the association increases the risk of death, and particularly death by completed suicide. From a clinical point of view, our results suggest a warning for metformin-treated diabetic patients receiving hydroxychloroquine, for example as self-medication or in off-label use for COVID-19.
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